Skip to main content
OpenTrials

Clinical trial condition

Non-muscle-invasive Bladder Cancer

Explore clinical trials studying Non-muscle-invasive Bladder Cancer. Study availability and eligibility vary by location and protocol.

19 public trials 11 recruiting studies
Refine in advanced search Browse all conditions

Non-muscle-invasive Bladder Cancer trial results

Completed

A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X)

NCT03664258

Conditions
Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +13 more
Locations
  • University Clinic for Urology and Andrology Salzburg, Austria
  • Medical University of Vienna Vienna, Austria
  • Teaching Hospital Motol Prague, Czechia
  • CHU Toulouse / Institut Universitaire du Cancer Toulouse Oncopole Toulouse, France
View all 13 locations
View Trial Details
Active, Not Recruiting

Intravesical BCG vs GEMDOCE in NMIBC

NCT05538663

Conditions
Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +13 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Fairbanks Memorial Hospital Fairbanks, Alaska, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
View all 229 locations
View Trial Details
Active, Not Recruiting

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

NCT03528694

Conditions
Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +13 more
Locations
  • Research Site Auchenflower, Australia
  • Research Site Box Hill, Australia
  • Research Site Brisbane, Australia
  • Research Site Kogarah, Australia
View all 120 locations
View Trial Details
Active, Not Recruiting

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

NCT05544552

Conditions
Advanced Solid Tumor, Advanced Urothelial Carcinoma, Bladder Cancer, +31 more
Locations
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • UMass Memorial Medical Center Worchester, Massachusetts, United States
  • Memorial Sloan Kettering Cancer Center (MSKCC) New York, United States
  • Duke Cancer Institute (DCI) - Duke Cancer Center Durham, North Carolina, United States
View all 19 locations
View Trial Details

Related conditions